What factors drove the changes in Orthofix Medical's revenue and profit?

What is the market's earnings forecast for Orthofix Medical next quarter?

Did Orthofix Medical beat or miss consensus estimates last quarter?

What does Orthofix Medical do and what are its main business segments?

What is the revenue and EPS growth rate for Orthofix Medical year over year?

What were the key takeaways from Orthofix Medical's earnings call?

What is Orthofix Medical's latest dividend and current dividend yield?

What guidance did Orthofix Medical's management provide for the next earnings period?

- **Revenue growth beats expectations**: North American market recovery drove a 15% YoY increase in revenue.
- **AI strategy success**: 7D Flash Navigation adoption up 24% in key segments.
- **Non-GAAP EPS beats**: Strong cost control improved operational efficiency to $1.08.
- **2025 guidance**: $810-814M net sales, $84-86M EBITDA, positive free cash flow.
- **2026 outlook**: 6.5-7.5% CAGR driven by Virada launch and 7D-enabled innovation.

**【CEO Opening Remarks】**
- Q3 revenue growth driven by 19% US orthopedics and 10% procedural volume in spine fixation, outperforming market with 7D Flash Navigation adoption.
- Launched Virada Spinal Fixation System, integrating 7D technology for enhanced surgical workflow efficiency.
- 2025 guidance: Pro forma net sales $810-814M, EBITDA $84-86M, free cash flow positive.

**【CFO Financial Commentary】**
- Q3 GAAP net income $420M, Non-GAAP EPS $1.08 vs. $0.95 consensus.
- Orthopedics growth 19% YoY, driven by TrueLok Elevate and FitBone implants.
- 2025 free cash flow positive, excluding M6 impact.

**【Q&A Highlights】**
- Distributor transitions driving 25% YoY growth in top 30 US partners.
- Virada launch targeting $2B pedicle screw market with 4-5% CAGR.
- 2026 guidance: Focus on Virada adoption and 7D-enabled margin expansion.
- 2025 gross margin 72%, operating expenses down 200bps YoY.
- 2026 targets: 6.5-7.5% CAGR, excluding M6, supported by new product pipeline.


Orthofix Medical Inc.(OFIX)-20251104-2025 Q3 Earnings call transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

OFIX

OFIX fundamentals

You can ask Aime